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To properly evaluate therapies for cutaneous dermatomyositis (DM), it is essential to administer an outcome
instrument that is reliable, valid, and responsive to clinical change, particularly when measuring disease activity.
The purpose of this study was to compare two skin severity DM outcome measures, the Cutaneous Disease and
Activity Severity Index (CDASI) and the Cutaneous Assessment Tool—Binary Method (CAT-BM), with the
Physician Global Assessment (PGA) as the ‘‘gold standard’’. Ten dermatologists evaluated 14 patients with DM
using the CDASI, CAT-BM, and PGA scales. Inter- and intra-rater reliability, validity, responsiveness, and
completion time were compared for each outcome instrument. Responsiveness was assessed from a different
study population, where one physician evaluated 35 patients with 110 visits. The CDASI was found to have a
higher inter- and intra-rater reliability. Regarding construct validity, both the CDASI and the CAT-BM were
significant predictors of the PGA scales. The CDASI had the best responsiveness among the three outcome
instruments examined. The CDASI had a statistically longer completion time than the CAT-BM by about
1.5minutes. The small patient population may limit the external validity of the findings observed. The CDASI is a
better clinical tool to assess skin severity in DM.
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INTRODUCTION
Dermatomyositis (DM) is a chronic systemic autoimmune
disease categorized among the idiopathic inflammatory
myopathies (Dugan et al, 2009). DM is often associated
with extramuscular and extracutaneous pathology, with
involvement of the joints, heart (cardiomyopathy and
conduction defects), and lungs (Iorizzo and Jorizzo, 2008).
The most widely accepted classification criteria for DM has
traditionally emphasized the importance of clinical, labora-
tory, histopathological, or electrophysiological evidence of
muscle inflammation for making the diagnosis (Bohan and
Peter, 1975a, b). Subtypes of DM, amyopathic and hypomyo-
pathic DM, have been described for patients with no or minor
muscle findings, respectively (Gerami et al., 2006).
Characteristic inflammatory skin changes are seen in a
large majority of individuals with DM (Callen and Wortmann,
2006). Nevertheless, the cutaneous manifestations of DM are
among the least systemically studied aspects of the disease.
This has resulted in part from the lack of validated tools to
reliably determine the activity of the cutaneous manifesta-
tions of DM, especially relative to other dermatological
diseases such as psoriasis and atopic dermatitis, where
disease-specific skin severity outcome instruments have
been used extensively (Kunz et al, 1997; Feldman and
Kruger, 2005; Mrowietz et al., 2006; Gaines and Werth,
2008). The Federal Drug Administration has developed
guidelines for researchers on how to measure clinical
response through measuring disease activity, disease-induced
damage, the response as determined by the patient, and
health-related quality of life (Guidance for Industry Systemic
Lupus Erythematosus, 2010; Gaines and Werth, 2008). From
these guidelines, researchers must develop an outcome
instrument that will capture appropriate elements of the
disease to determine clinical response.
Currently, effective treatments for the cutaneous mani-
festation of DM are limited. There are a number of new
biological therapies that may be beneficial for patients
with DM (Iorizzo and Jorizzo, 2008). There is a critical need
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to develop optimal validated instruments to quantify
organ-specific disease activity, so that the efficacy of medi-
cations can be methodically and quantitatively evaluated.
We have previously validated a cutaneous severity out-
come instrument, the Cutaneous Dermatomyositis Disease
Area and Severity Index (CDASI), and have shown that it
may be a more effective and reliable tool compared with
other outcome measures, namely the Dermatomyositis Skin
Severity Index (DSSI) and the Cutaneous Assessment Tool
(CAT; Klein et al., 2008). To further simplify the CDASI, we
have revised the original CDASI and have shown that the
modified version correlates almost perfectly with the original
CDASI (Yassaee et al., 2010). The CAT was originally
developed with similar goals to the CDASI and was found
to have appropriate reliability, construct validity, and
responsiveness in the juvenile DM population (Huber et al.,
2007, 2008a, b). Recently, the CAT has also been simpli-
fied, and has been validated in the juvenile population
(Huber et al., 2008a, b). The modified versions of the
CAT, named CAT-Binary Method (CAT-BM) and CAT-
Maximum Method (CAT-MM), stem from an alternative
scoring method of the CAT. The CAT-BM has been shown
to correlate almost perfectly to the original CAT (Huber et al.,
2008a, b). As yet, there are no studies comparing the
modified CDASI and the CAT-BM for use in longitudinal
clinical research.
The current study evaluates and compares the modified
tools, with a goal to provide partial validation of each tool for
use in the adult DM population and to determine the optimal
effective research tool for measuring the severity of cutaneous
disease in adult DM. The goal is to establish an appropriate
tool for evaluating DM within and between studies to
evaluate therapeutic responses most effectively.
RESULTS
Distribution of scores
CDASI Total and CAT-BM Total scores had a normal
distribution with scores ranging from 1 to 72 and from 1 to
20, respectively (CDASI Total: mean 24.25±14.67; CAT-BM
Total: mean 9.24±4.17).
Inter-rater reliability
Inter-rater reliability was assessed by determining the
agreement between the CDASI and the CAT-BM scores from
the 10 physician raters. The CDASI was found to have good
inter-rater reliability among activity and total scores and
moderate inter-rater reliability in damage scores, meaning
the scores among physicians were in good accordance with
one another among activity and total scores and in moderate
accordance with one another among damage scores.
Contrastingly, the CAT-BM was found to have moderate
inter-rater reliability in activity scores and poor inter-rater
reliability among damage and total scores. The CDASI had
the best inter-rater reliability overall when compared with the
CAT-BM and PGA scales (Activity: CDASI 0.748, CAT-BM
0.516, PGA Activity 0.721, PGA Activity Likert 0.653;
Damage: CDASI 0.563, CAT-BM 0.340, PGA Damage
0.506, PGA Damage Likert 0.542; Total CDASI 0.726,
CAT-BM 0.432, PGA Overall 0.632, PGA Overall Likert
0.694; Table 1).
Intra-rater reliability
Intra-rater reliability measures the degree of agreement of
multiple outcome scores performed by a single physician. It
was assessed by determining the agreement between initial
and repeat scores, using the intraclass correlation coefficient
(ICC), for each outcome instrument, as well as determining
the significance of a difference between mean initial scores
and mean repeat scores for each outcome instrument. The
CDASI was found to have an almost perfect intra-rater
reliability between activity and total scores and good intra-
rater reliability with damage scores (ICC: Activity 0.868;
Damage 0.800; Total 0.903). No significant difference
between mean initial and mean repeat activity, damage,
and total scores was found (mean difference: Activity 0.00,
P¼1.00; Damage 0.40, P¼0.728; Total 0.40, P¼0.541).
The CAT-BM was found to have good intra-rater reliability
between activity, damage scores, and total scores (ICC:
Activity 0.714; Damage 0.792; Total 0.800). No significant
difference between mean initial and mean repeat activity,
damage, and total scores was found (mean difference:
Activity 0.2, P¼0.713; Damage 0.35, P¼ 0.496; Total
0.15, P¼0.634). PGA scales were found to have almost
perfect intra-rater reliability in all assessments except for PGA
Activity Likert and PGA Damage Likert (ICC: 0.737 and
0.708, respectively). There was also a significant difference
between initial and repeat mean scores for PGA Overall and
Table 1. Assessment of inter-rater reliability
Inter-rater reliability ICC 95% CI
CDASI
Activity 0.748 0.553–0.895
Damage 0.563 0.358–0.785
Total 0.726 0.527–0.883
CAT-BM
Activity 0.516 0.318–0.751
Damage 0.34 0.172–0.602
Total 0.432 0.241–0.687
PGA—Activity 0.721 0.540–0.877
PGA—Activity Likert 0.653 0.446–0.860
PGA—Damage 0.506 0.313–0.743
PGA—Damage Likert 0.542 0.329–0.797
PGA—Overall 0.632 0.422–0.835
PGA—Overall Likert 0.694 0.486–0.889
Abbreviations: CAT-BM, Cutaneous Assessment Tool—Binary Method;
CDASI, Cutaneous Dermatomyositis Disease Area and Severity Index;
CI, confidence interval; ICC, intraclass correlation coefficient; PGA,
Physician Global Assessment.
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PGA Activity Likert (mean difference: PGA Overall 0.63,
P¼0.019; PGA Activity Likert 0.24, P¼0.021; Table 2).
Construct validity
Validity was assessed for the CDASI and the CAT-BM using a
linear mixed model. Both the CDASI and the CAT-BM were
found to be significant predictors of the compared ‘‘gold
standard’’, the PGA scales using both the Visual Analogue
Scale (VAS) and the Likert scale (all Pp0.001 among total,
activity, and damage scores; Table 3), indicating that both the
CDASI and the CAT-BM were good predictors of both the
VAS and the Likert PGA scales.
As another means to assess construct validity and linearity,
the CDASI and CAT-BM scores were grouped by Likert scores.
All CDASI and CAT-BM mean scores (Total, Activity, and
Damage) expressed statistically significant distinct values when
grouped by Likert scores (all P-values p0.001; Table 4),
reaffirming that both tools are good predictors of the Likert PGA
scales. Furthermore, both the CDASI and CAT-BM expressed a
significant, near-perfect fit for linearity with all coefficient of
determination values, or r2 values X0.947 (highest P¼0.026).
Content validity
All the physicians felt that the CDASI was complete, although
one physician noted that it may be useful to have a
mechanism to capture lipoatrophy from panniculitis in
patients. Nine of the ten physicians felt that the CAT-BM
was complete. One physician felt that the CAT-BM did not
adequately assess the scalp.
Responsiveness
Responsiveness was measured using the standardized
response mean (SRM), defined as the ratio of the mean of
the differences (i.e., CDASI and CAT-BM scores before and
after a clinical change were noted) between two time points
to the standard deviation of the differences. The CDASI
had the highest SRM among outcome instruments (SRM:
CDASI 1.25; CAT-BM 0.93; PGA Activity 1.03; PGA Activity
Likert 0.61). The CDASI was the only instrument to have
an SRM 41, indicating that the mean change between visits
was greater than the standard deviation change between
visits. As mentioned above, the CDASI had the highest intra-
rater reliability among all compared outcome instruments
(Table 2).
Completion time
The CDASI had a statistically longer completion time than
the CAT-BM (completion time: CDASI 4.76minutes; CAT-BM
3.19minutes; Po0.001) with a mean time difference of
1.58minutes (95% confidence interval 1.18–1.97minutes).
Physician exit questionnaire
Six of the ten physicians felt that the CDASI would be more
easily incorporated in a clinical setting than the CAT-BM.
Those who preferred the CDASI mentioned the likelihood
that it would be a more effective instrument to assess
responsiveness, as well as the order in which the anatomical
locations were organized. Contrastingly, those who preferred
the CAT-BM stated that it was a quicker instrument to
complete. Six of the ten physicians felt that the CAT-BM was
less difficult to use. Those who preferred the CAT-BM
mentioned that it was quicker to complete, whereas those
who preferred the CDASI stated that the CAT-BM was
‘‘poorly organized’’ and that they would need to ‘‘jump
around’’ while completing it. All the 10 physicians felt that
the CDASI was a better instrument to grade skin severity
and improvement over time. Physicians commented that the
CDASI measures the ‘‘degree of intensity of an eruption,’’
whereas a ‘‘binary [method] would not be helpful in
estimating response to treatment’’ and would ‘‘need to have
complete resolution to capture change.’’ Furthermore, one
physician commented that the CAT-BM included livedo
reticularis in its scoring, which ‘‘would not be expected to
improve with most therapy.’’
DISCUSSION
Validated outcome measures have an important role in
standardizing patient care and in developing reliable clinical
trials by objectively measuring the severity of disease. The
scientific method states the importance of attaining repro-
ducible results. An outcome measure, therefore, must also be
reproducible in order to adequately function in future clinical
trials. The importance of an outcome measure’s reliability,
Table 2. Intra-rater reliability—ICC and mean
differences of initial and repeat scores
ICC 95% CI
Mean difference
between initial
and repeat score P-value
CDASI
Activity 0.868 0.696–0.946 0 1.000
Damage 0.8 0.564–0.916 0.40 0.728
Total 0.903 0.770–0.960 0.40 0.541
CAT-BM
Activity 0.714 0.409–0.876 0.20 0.713
Damage 0.792 0.547–0.912 0.35 0.496
Total 0.8 0.561–0.916 0.15 0.634
PGA—Activity 0.911 0.788–0.964 0.04 0.859
PGA—Activity
Likert
0.737 0.399–0.892 0.24 0.021
PGA—Damage 0.814 0.587–0.922 0.09 0.815
PGA—Damage
Likert
0.708 0.382–0.877 0.05 0.716
PGA—Overall 0.887 0.673–0.958 0.63 0.019
PGA—Overall
Likert
0.875 0.703–0.950 0 1.000
Abbreviations: CAT-BM, Cutaneous Assessment Tool—Binary Method;
CDASI, Cutaneous Dermatomyositis Disease Area and Severity Index;
CI, confidence interval; ICC, intraclass correlation coefficient; PGA,
Physician Global Assessment.
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which measures reproducibility, is clearly important and is
necessary for attaining validity (Klein et al., 2008; Downing,
2004). ICC values were compared via the method described
by Steel et al. (1997). Although post-hoc power analysis
showed that the difference in ICC scores did not reach
statistical significance, there is a trend that the CDASI has
good inter-rater reliability with regard to its Activity and Total
measurements, whereas the CAT-BM has moderate and poor
inter-rater reliability for its Activity and Total measurements,
respectively (Table 1). Likely, the nature of the instruments
lends the CDASI to having a higher inter-rater reliability, even
though the CAT-BM is a binary instrument. For example, an
item on the CAT-BM that was seen to have a large standard
deviation among raters was the item scoring the presence of
non-sun exposed erythema. As the CDASI has five to six
items that would qualify as non-sun exposed erythema in
addition to a larger number of items contributing to the
activity score, it lends itself to having an intrinsically high
inter-rater reliability, as one disagreement among physicians
would have less of an impact on the overall reliability than in
the CAT-BM. In addition, it is also possible that as the CDASI
specifically goes through all anatomical parts, it gives more
‘‘pressure’’ to the rater to look through all the parts more
efficiently than in the CAT-BM. Third, the ambiguousness of
certain question items in the CAT-BM may have contributed
to a lower reliability. For example, the items scoring the
presence of cuticular overgrowth or subcutaneous edema
were seen to have a large standard deviation among raters.
Although the CDASI may not be a binary system, the
measures of activity that it scores (erythema, scale, and
erosions) are defined more clearly among physicians than
certain measures of activity in the CAT-BM. Notably, the
inter-rater reliability among activity scores in the initial study
exploring the CAT-BM (Huber et al. 2008a, b) reports an ICC
score of 0.6 (95% confidence interval 0.06–0.83), contrasting
to our reported value of 0.34. Although our value of 0.34 lies
within the 95% confidence interval making statistical
variability the most likely cause for the difference, the
differing patient populations between the studies (adult vs.
juvenile) may have also had a role.
Interestingly, inter-rater reliability of damage measure-
ments was lower in both the CDASI, the CAT-BM, and PGA
scales (Table 1, ICC: CDASI Damage 0.563; CAT-BM 0.340;
PGA Damage 0.506, PGA Damage Likert 0.542). This is
consistent for other outcome instruments that contain a
damage subscore such as the CAT and the previous version of
the CDASI, suggesting that physicians have difficulty agreeing
with one another in their assessment of damage (Shrout and
Fleiss, 1979). It was noted that in the physician training
session, the concept of poikiloderma varied among physi-
cians. In addition, in a previous study, agreement of a
physician’s perception of poikiloderma was poor as well
(Klein et al., 2008). Poikiloderma accounts for almost half,
less than 10%, and theoretically 100% of the maximum
damage score in the CDASI, the CAT-BM, and the PGA
Damage scales, respectively. This suggests that there is
Table 3. Assessment of construct validity between the CDASI and the CAT-BM
CDASI Activity CAT-BM Activity CDASI Activity CAT-BM Activity
PGA Activity PGA Activity Likert
Parameter estimate 1.96 0.61 Parameter estimate 3.8 1.52
SE 0.299 0.09 SE 1.07 0.34
F 42.97 48.12 F 12.56 19.66
P o0.001 o0.001 P 0.001 o0.001
CDASI Damage CAT-BM Damage CDASI Damage CAT-BM Damage
PGA Damage PGA Damage Likert
Parameter estimate 0.72 0.51 Parameter estimate 1.74 1.6
SE 0.1 0.06 SE 0.33 0.18
F 49 80.68 F 28.3 78.12
P o0.001 o0.001 P o0.001 o0.001
CDASI Total CAT-BM Total CDASI Total CAT-BM Total
PGA Overall PGA Overall Likert
Parameter estimate 2.14 0.96 Parameter estimate 6.65 2.96
SE 0.36 0.12 SE 1.31 0.45
F 35.65 60.93 F 25.68 42.4
P o0.001 o0.001 P o0.001 o0.001
Abbreviations: CAT-BM, Cutaneous Assessment Tool—Binary Method; CDASI, Cutaneous Dermatomyositis Disease Area and Severity Index; PGA,
Physician Global Assessment.
Data derived by using PGA values as a fixed-effect covariate and physician subject # and patient subject # as a random-effect factor. P-valueso0.05 indicate
that the outcome instrument score is a significant predictor of the ‘‘gold standard’’, its PGA counterpart. Comparisons between the CDASI and the CAT-BM
cannot be made.
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another factor, perhaps an inherent limitation of the outcome
measure, explaining the poor, and lower, inter-rater relia-
bility of the CAT-BM when compared with the CDASI or PGA
Damage scales.
The intra-rater reliability of the CDASI was almost perfect in
activity and total scores and good across damage scores. The
CAT-BM had a lower intra-reliability across activity, damage,
and total scores with good intra-rater reliability in all realms
(Table 2). Although this shows a trend that the CDASI has a
better intra-rater reliability, post-hoc power analysis showed
that the difference did not reach statistical significance.
Although an outcome instrument may be reliable, if it does
not have adequate construct validity, or the ability to measure
what it has been designed to measure effectively, then its
usefulness is limited. Both the CDASI and the CAT-BM were
shown to be significant predictors of PGA scales, which is the
‘‘gold standard’’, and thus to have good construct validity.
Although both the CDASI and the CAT-BM were found to have
good content validity as stated above, a physician noted that
the CAT-BM did not sufficiently assess scalp disease, which
can be very troublesome for patients and was found in over
80% in the DM population (Kasteler and Callen, 1994; Tilstra
et al., 2009).
It is also important for an outcome instrument to be able
to capture the disease state of patients at the extremes of
disease. This is particularly important in patients with
extreme disease activity. In this study, the maximum CDASI
Activity and CAT-BM Activity score reached was 61 (61% of
maximum activity score) and 14 (82% of maximum activity
score), respectively. This suggests that the CAT-BM may be
more prone to reach its maximum limit faster than the CDASI,
and therefore not be able to capture differences in disease
activity in more severe patients.
To implement an outcome instrument for the use of
clinical trials, it is essential that it be able to measure changes
in disease severity. The CDASI had the best responsiveness
when compared with CAT-BM and PGA scales. Furthermore,
all physicians anticipated that the CDASI would be a more
effective response tool than the CAT-BM. This was not a
surprising result, as shown by many of the physician rater
comments, predicting that the CAT-BM would have this
limitation as it only documents presence or absence of a
certain measure, whereas the CDASI documents the degree
of severity of a certain measure.
Another important factor when comparing outcome instru-
ments is its completion time. Even a tool that is reliable and
valid but takes too long to complete would not be practical in
a clinical research setting. Although the CAT-BM took
significantly less time to complete than the CDASI (Mean
completion time: CAT-BM 3.19minutes; CDASI 4.76minutes;
Po0.001), the mean difference in completion time was about
90 seconds and may not be practically relevant.
There were limitations to the study. First, as the patient
population was relatively small, the external validity of our
Table 4. Determination of differences among CDASI and CAT-BM scores when grouped by Likert score with linear
trend of means
CDASI Activity CAT-BM Activity
Likert score N Mean SD P r2 Linear trend P N Mean SD P r 2 Linear trend P
0 3 0.33 0.58 o0.001 0.985 0.001 3 0.67 0.58 o0.001 0.947 0.005
1 79 11.44 6.96 79 5.04 2.36
2 40 25.65 8.95 40 8.00 1.96
3 13 39.38 7.25 13 9.77 1.79
4 2 42.50 0.71 2 10.50 0.71
Total 137 18.45 12.52 137 6.34 2.91
CDASI Damage CAT-BM Damage
0 16 0.50 0.89 o0.001 0.949 0.005 16 0.19 0.54 o0.001 0.964 0.003
1 69 4.20 2.93 69 2.33 1.60
2 39 8.51 2.85 39 4.15 1.95
3 13 10.62 3.38 13 5.69 1.65
Total 137 5.61 4.07 137 2.92 2.20
CDASI Total CAT-BM Total
1 71 14.21 7.38 o0.001 0.950 0.026 71 6.85 3.11 o0.001 0.993 0.004
2 47 30.26 10.00 47 10.94 3.26
3 16 49.50 9.48 16 14.63 2.92
4 1 51.00 — 1 16.00 —
Total 135 24.25 14.84 135 9.26 4.18
Abbreviations: CAT-BM, Cutaneous Assessment Tool—Binary Method; CDASI, Cutaneous Dermatomyositis Disease Area and Severity Index.
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findings may be limited. Many results were not able to reach
statistical significance because of a small patient population.
For example, post-hoc power analysis showed that a patient
population of 60 would be needed to reach statistical
significance between the ICC scores. Second, the relatively
small patient population may have allowed the physician
raters to recall how they evaluated a patient when completing
their repeat evaluation. This could potentially raise the intra-
rater reliability from its true value. To minimize this impact,
physicians were asked to perform their repeat evaluation on a
patient they had evaluated during the morning session, thus
minimizing a likelihood of recall. Third, as the study session
lasted about 7 hours, it is possible that the physicians may
have experienced fatigue that may have impacted their
patient evaluation. This was minimized by offering snacks
and lunch during the day and allowing physicians to rate
patients at their own pace. Fourth, five of the ten physician
participants have used both the CAT and the original version
of the CDASI previously, which may have falsely elevated the
reliability and validity scores in both instruments, as many
physicians had increased familiarity with both the instru-
ments. Regardless of the limitations above, we can conclude
that the CDASI appears to be a more effective tool than the
CAT-BM in evaluating cutaneous severity in DM.
MATERIALS AND METHODS
This study has been approved by the local Institutional Review
Board. The Declaration of Helsinki Principles protocols was adhered
and physician and patient participants gave their written, informed
consent before study initiation.
Physician participants
A total of 10 dermatology-boarded physicians were invited to
participate in the 1-day study at the Hospital of the University of
Pennsylvania. Physicians were given the CDASI and the CAT-BM, as
well as corresponding literature before the study session day so that
they may better familiarize themselves with the tools. On the study
session day, before initiating the study, the physicians were given a
training session with visual examples in order to score all study
instruments correctly. Adequate time was given to the physicians to
address any questions and/or clarifications they may have had
regarding the outcome instruments.
Patient participants
A total of 14 patients with the clinical and/or pathological evidence of
DM were invited to participate in the study at the Hospital of the
University of Pennsylvania. The patients represented a wide spectrum
of diseases. The patient population consisted of 14 Caucasians, 3 men,
11 women, with varying degrees of muscle and cutaneous involve-
ment (noted to have PGA Activity scores ranging from 0 to 9.3 with
a mean of 3.2±2.8; PGA Damage scores ranging from 0 to 9.4 with a
mean of 2.8±2.6; and PGA Overall scores ranging from 0.2 to 9.2
with a mean of 3.4±2.5). Average age of participants was 53±16.
Average duration of disease among patients was not recorded.
Study design
The study day was divided into Session 1 and Session 2. Each physi-
cian was given a randomized number from 1 to 10 and consequently
a folder corresponding to their number. On the basis of the assigned
number, physicians were divided into two groups of five physi-
cians—Group 1Ph and Group 2Ph. One physician group contained
folders with packets of each outcome instrument in the order of
CDASI, CAT-BM, and PGA scales for Session 1 and packets of each
outcome instrument in the order of CAT-BM, CDASI, and PGA scales
for Session 2. The remaining physician group contained folders with
a reverse order of packets (i.e., CAT-BM, CDASI, and PGA scales for
Session 1). All folders from both the physician groups also contained
two packets of each outcome instrument for re-rates. All physicians
evaluated 14 patients. All physicians also reevaluated two patients.
At the end of the study session, physicians were given an exit
questionnaire consisting of seven questions, each of which consist-
ing of a short answer and four questions including a multiple-
choice part. Patients were randomized and divided into two groups:
Group 1P, consisting of eight patients, and Group 2P, consisting
of six patients. During Session 1, Group 1Ph evaluated Group 1P and
Group 2Ph evaluated Group 2P. During Session 2, Group 1Ph
evaluated Group 2P and Group 2Ph evaluated Group 1P. No more
than one physician was permitted per patient encounter at any time.
CDASI
The CDASI is a one-page, partially validated outcome instrument
used to determine the severity of cutaneous disease specific to DM.
Total scores range from 0 to 132. Scores are divided into activity and
damage, with scores ranging from 0 to 100 and 0 to 32, respectively.
Neither activity nor damage is scored by percentage of body surface
area involvement. Disease activity is assessed by the degree of
erythema, scale, and the presence of erosions or ulcerations in 15
different anatomical locations. Disease damage is assessed by
presence of poikiloderma or calcinosis in the 15 different anatomical
locations. Periungual changes were scored from 0 to 2, with 0
indicating no periungual changes, 1 indicating periungual erythema,
and 2 indicating visible telangectasias. Alopecia scores range from 0
to 1, with zero indicating no alopecia in the last 30 days and 1
indicating presence of alopecia in the last 30 days. Gottron’s sign on
the knuckles are assessed similarly to the erythema scale used in
other anatomical locations. When Gottron’s papules were present,
the erythema score obtained on the knuckles was doubled.
CAT-BM
The CAT-BM is a one-page, normally distributed validated outcome
instrument derived from an alternative scoring method of the CAT
that is used to determine the severity of cutaneous disease in DM.
Total scores range from 0 to 28 and 0 to 17 for activity and from 0 to
11 for damage. Neither activity nor damage is scored by percentage
of body surface area involvement. Activity scores are based on the
presence of erythema in seven different anatomic areas and presence
of other characteristic DM lesions. Secondary changes such as
scales, erosions, or necrosis are not captured. Disease damage
is scored by the presence of atrophy or dyspigmentation without
erythema in the same seven different anatomic areas, as well as
presence of poikiloderma, calcinosis, lipoatrophy, or a depressed
scar anywhere on the body.
Assessment of inter- and intra-rater reliability
To assess intra-rater reliability, after a physician participant had
completed all patient encounters, they were asked to reevaluate
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two patients whom they had seen during the morning session
(to minimize physician recollection of scoring). Although physi-
cians arbitrarily decided which patient to re-rate on the basis
of patient availability, it was ensured that no patient would
be re-rated more than twice. Inter-rater reliability was used to
assess accordance of scores among physicians. All physicians
re-rated two patients. Inter-rater reliability was determined by the
10 physicians who evaluated all the 14 patients. Physicians also
recorded the time to complete each instrument for each patient
encounter.
Validation measures
To assess and compare validity among different outcome instru-
ments, three validation measures were used: (1) the Overall
Skin-Physician Global Assessment (PGA Overall), (2) the Skin
Activity-Physician Global Assessment (PGA Activity), and (3) the
Skin Damage-Physician Global Assessment (PGA Damage). Scores
were captured using VAS and Likert scales. The VAS is a continuous
scale ranging from 0 to 10, where 10 represents extremely active
disease. The Likert scale ranges from 0 to 4, where 4 represents
extremely severe disease.
Assessment of validity
Specifically, convergent construct validity was determined by
comparing the Skin Activity-PGA to the activity scores of the activity
subscore of the outcome instruments, comparing the Skin Damage-
PGA to the damage subscore of the outcome instruments, and
comparing the Overall Skin-PGA to the overall score of the outcome
instruments. Convergent construct validity refers to the degree one
measure (i.e., the CDASI or the CAT-BM) correlates to another
measure (i.e., the corresponding PGA) that it theoretically should
correlate with. The PGAs were also used to determine whether
either of the outcome instruments was skewed to any direction,
which could potentially limit the usefulness in longitudinal studies.
Content validity was determined by administrating the Physician
Exit Questionnaire, which includes the question ‘‘Was there any
information missing from any of the measures that you feel should
be added?’’
Responsiveness
Responsiveness was assessed from prospective visit data collected
separately from the inter- and intra-rater validation studies. This
included assessments of the CDASI, CAT-BM, and PGA scale scores,
as well as an overall evaluation from the physician as to whether the
patient had improved, worsened, or had no change from their
previous research visit. A total of 35 patients with a cumulative 110
visits were obtained from this data source. There were 27 visits in
which a clinical change was noted. The largest clinical change per
patient, defined as the largest difference in the PGA-Activity score
between two consecutive visits, was included in the analysis.
The SRM was used to determine responsiveness for the CDASI and
the CAT-BM. The SRM measures the ratio of the mean of the
differences (i.e., CDASI and CAT-BM scores before and after a
clinical change was noted) between two time points to the standard
deviation of the differences. The absolute mean change was used
between visits to account for improvement and worsening of disease.
This approach has been used in the past (Beaton et al., 1997;
Ruperto et al., 2010).
Statistical methods
Statistical analyses were performed using statistical programs STATA
and SPSS. Inter-rater reliability was determined by ICC, type ICC (2,1),
via Shrout and Fleiss convention (Shrout and Fleiss, 1979). Previous
research has dictated that an ICC between 0.5 and 0.7 to be moderate,
between 0.70 and 0.81 to be good, and an ICC X0.81 to be almost
perfect (Landis and Koch, 1977; Klein et al., 2008). Intra-rater
reliability was determined by ICC (2,1) and paired, two-tailed t-test
comparing mean scores between initial and repeat scores of each
instrument. Construct validity was assessed by testing the association
between outcomemeasure (CDASI or CAT-BM) and the corresponding
validation measure. Because each patient and each physician had
repeated measures, we used a linear mixed model for this test,
adjusting for within-patient and within-physician variations. Other
covariates, such as age and gender, were not seen to have an
influence. Physician subject # and patient subject # were placed as
random-effect factors, whereas PGA scores were placed as a fixed-
effect covariate. Likert scores were also used as an additional means to
assess construct validity. Differences in CDASI and CAT-BM scores
when grouped by corresponding Likert scores were evaluated using
one-way analysis of variance. Linear regression was also used on mean
CDASI and CAT-BM scores of each Likert group to determine linearity.
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